AU2013257533A1 - Pharmaceutical compositions resistant to abuse - Google Patents
Pharmaceutical compositions resistant to abuseInfo
- Publication number
- AU2013257533A1 AU2013257533A1 AU2013257533A AU2013257533A AU2013257533A1 AU 2013257533 A1 AU2013257533 A1 AU 2013257533A1 AU 2013257533 A AU2013257533 A AU 2013257533A AU 2013257533 A AU2013257533 A AU 2013257533A AU 2013257533 A1 AU2013257533 A1 AU 2013257533A1
- Authority
- AU
- Australia
- Prior art keywords
- abuse
- pharmaceutical compositions
- compositions resistant
- resistant
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013257533A AU2013257533B2 (en) | 2009-02-06 | 2013-11-19 | Pharmaceutical compositions resistant to abuse |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/150,620 | 2009-02-06 | ||
DKPA200900192 | 2009-02-06 | ||
DKPA200900192 | 2009-02-06 | ||
AU2010211376A AU2010211376B2 (en) | 2009-02-06 | 2010-02-05 | Pharmaceutical compositions resistant to abuse |
AU2013257533A AU2013257533B2 (en) | 2009-02-06 | 2013-11-19 | Pharmaceutical compositions resistant to abuse |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2010211376A Division AU2010211376B2 (en) | 2009-02-06 | 2010-02-05 | Pharmaceutical compositions resistant to abuse |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2013257533A1 true AU2013257533A1 (en) | 2013-12-05 |
AU2013257533B2 AU2013257533B2 (en) | 2016-05-19 |
Family
ID=40732263
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2010211376A Ceased AU2010211376B2 (en) | 2009-02-06 | 2010-02-05 | Pharmaceutical compositions resistant to abuse |
AU2013257533A Ceased AU2013257533B2 (en) | 2009-02-06 | 2013-11-19 | Pharmaceutical compositions resistant to abuse |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2010211376A Ceased AU2010211376B2 (en) | 2009-02-06 | 2010-02-05 | Pharmaceutical compositions resistant to abuse |
Country Status (10)
Country | Link |
---|---|
US (4) | US8603526B2 (en) |
EP (2) | EP3184105A1 (en) |
AU (2) | AU2010211376B2 (en) |
CA (1) | CA2751627A1 (en) |
DK (1) | DK2393487T3 (en) |
ES (1) | ES2607209T3 (en) |
IL (1) | IL214354A0 (en) |
NZ (1) | NZ594208A (en) |
WO (1) | WO2010088911A1 (en) |
ZA (1) | ZA201105626B (en) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
ATE495732T1 (en) | 2003-03-26 | 2011-02-15 | Egalet As | CONTROLLED RELEASE MORPHINE SYSTEM |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US20100291205A1 (en) * | 2007-01-16 | 2010-11-18 | Egalet A/S | Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
JP5774853B2 (en) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Pharmaceutical dosage form |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
EP2700400A1 (en) * | 2009-01-26 | 2014-02-26 | Egalet Ltd. | Controlled release formulation with continuous efficacy |
NZ594208A (en) | 2009-02-06 | 2012-10-26 | Egalet Ltd | Pharmaceutical compositions resistant to abuse |
AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
MX2012000369A (en) | 2009-07-22 | 2012-02-01 | Gruenenthal Gmbh | Tamper-resistant dosage form for oxidation-sensitive oploids. |
MX2012000317A (en) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form. |
NZ603170A (en) | 2010-05-10 | 2015-04-24 | Euro Celtique Sa | Combination of active loaded granules with additional actives |
US9700508B2 (en) | 2010-05-10 | 2017-07-11 | Euro-Celtique S.A. | Pharmaceutical compositions comprising hydromorphone and naloxone |
AU2011252040C1 (en) | 2010-05-10 | 2015-04-02 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
ES2487244T3 (en) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Handling resistant dosage form comprising an anionic polymer |
RU2604676C2 (en) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing an inorganic salt |
TR201815766T4 (en) | 2011-06-23 | 2018-11-21 | British American Tobacco Investments Ltd | Filter material containing polylactide fibers. |
GB201112402D0 (en) | 2011-07-19 | 2011-08-31 | British American Tobacco Co | Cellulose acetate compositions |
PT2736495T (en) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US20150224097A1 (en) * | 2011-11-22 | 2015-08-13 | Watson Pharmaceuticals, Inc. | Immediate Release Abuse Deterrent Tablet |
WO2013125293A1 (en) * | 2012-02-24 | 2013-08-29 | Tanabe Atsushi | Vessel bottom cover and vessel |
BR112014019988A8 (en) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER |
JP6282261B2 (en) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Unauthorized use and overdose prevention pharmaceutical dosage forms |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
KR20150059167A (en) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | Abuse deterrent pharmaceutical compositions for controlled release |
CN102885796A (en) * | 2012-07-30 | 2013-01-23 | 永光制药有限公司 | Lacosamide tablet for treating epilepsy and preparation method for lacosamide tablet |
WO2014097302A1 (en) * | 2012-12-23 | 2014-06-26 | Zelikman Vadim | A gellan gum carrier for a medicament, means and method |
BR112015029616A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-resistant dosage form with bimodal release profile |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
AU2014350135B2 (en) | 2013-11-13 | 2017-08-31 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
MX371372B (en) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling. |
US20150164807A1 (en) | 2013-12-16 | 2015-06-18 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
MX2016008361A (en) * | 2013-12-23 | 2016-10-14 | Purdue Pharma Lp | Opioid antagonist formulations. |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
PT3164117T (en) | 2014-07-03 | 2023-12-12 | SpecGx LLC | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
CN107889459A (en) | 2015-04-24 | 2018-04-06 | 格吕伦塔尔有限公司 | Tamper resistant dosage form with release immediately and to solvent-extracted resistance |
WO2016200960A1 (en) * | 2015-06-09 | 2016-12-15 | KVK-Tech, Inc. | Abuse deterrent pharmaceutical compositions |
US11697242B2 (en) * | 2015-07-27 | 2023-07-11 | Nutrition & Biosciences Usa 1, Llc | Method to additive manufacture biocompatible material and articles made by the method |
AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
EP3413893A4 (en) * | 2016-02-08 | 2019-08-28 | SpecGx LLC | Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties |
US10653639B2 (en) | 2016-05-16 | 2020-05-19 | Cv Sciences, Inc. | Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction |
WO2018030956A1 (en) * | 2016-08-08 | 2018-02-15 | Structo Pte Ltd | A 3d printed article, method of use and method of manufacture |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
WO2019064082A2 (en) * | 2017-10-01 | 2019-04-04 | Patel Jayendrakumar Dasharathlal | Pharmaceutical abuse deterrent composition constructed in more than one strengths |
US11450447B2 (en) * | 2017-10-04 | 2022-09-20 | Solar Paste, Llc | Fine silver particle dispersion |
US11441010B2 (en) | 2017-10-04 | 2022-09-13 | Dowa Electronics Materials Co., Ltd. | Fine silver particle dispersion |
US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
AU2018348359C1 (en) * | 2017-10-10 | 2023-10-12 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation and methods of treatment |
US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
CA3112030A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
AU2020247549A1 (en) * | 2019-03-25 | 2021-09-09 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
US11227702B2 (en) | 2019-04-04 | 2022-01-18 | Dowa Electronics Materials Co., Ltd. | Fine silver particle dispersion |
KR20210059935A (en) | 2019-11-18 | 2021-05-26 | 주식회사 엘지화학 | Device for Charge and Discharge of Secondary Battery |
CN110921099B (en) * | 2019-11-26 | 2021-12-07 | 江苏金之虹新材料有限公司 | High-barrier biodegradable self-supporting bag and preparation method thereof |
WO2021178700A1 (en) * | 2020-03-04 | 2021-09-10 | Pleopharma, L.L.C. | Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal |
IL296166A (en) | 2020-03-04 | 2022-11-01 | Pleopharma L L C | Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal |
CN115667217A (en) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | Deuterated tryptamine derivatives and methods of use |
EP4387624A1 (en) * | 2021-08-19 | 2024-06-26 | Mind Medicine, Inc. | Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications |
CN113736119B (en) * | 2021-10-22 | 2022-04-15 | 北京工商大学 | Preparation method and application of biodegradable antioxidant fruit and vegetable preservative film |
WO2023133477A1 (en) * | 2022-01-06 | 2023-07-13 | Terran Biosciences, Inc. | Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2685553A (en) * | 1951-03-30 | 1954-08-03 | Winthrop Stearns Inc | Cement coated tablets |
US4034758A (en) * | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
US4449983A (en) * | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
US4898733A (en) * | 1985-11-04 | 1990-02-06 | International Minerals & Chemical Corp. | Layered, compression molded device for the sustained release of a beneficial agent |
EP0406315B1 (en) | 1988-03-24 | 1992-11-11 | Bukh Meditec A/S | Controlled release composition |
US5019396A (en) * | 1989-05-12 | 1991-05-28 | Alza Corporation | Delivery dispenser for treating cardiac arrhythmias |
DK469989D0 (en) | 1989-09-22 | 1989-09-22 | Bukh Meditec | PHARMACEUTICAL PREPARATION |
EP0435726B1 (en) | 1989-12-29 | 1994-11-09 | Bristol-Myers Squibb Company | Capsule and caplet combination |
US5609885A (en) * | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
WO1995022962A1 (en) | 1994-02-23 | 1995-08-31 | Bm Research A/S | Controlled release composition |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
EP1067910B1 (en) | 1998-04-03 | 2004-05-26 | Egalet A/S | Controlled release composition |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
ATE293439T1 (en) | 2000-12-07 | 2005-05-15 | Warner Lambert Co | METHOD AND SYSTEM FOR EVEN DELIVERY OF DRUGS |
WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
EP1929998A3 (en) | 2001-09-21 | 2008-11-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
CN1638740A (en) * | 2001-09-28 | 2005-07-13 | 麦克内尔-Ppc股份有限公司 | Modified release dosage forms |
ITMI20020514A1 (en) | 2002-03-12 | 2003-09-12 | Jagotec Ag | THERAPEUTIC SYSTEM FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE PRINCIPLES |
AU2003220551A1 (en) | 2002-03-26 | 2003-10-13 | Euro-Celtique S.A. | Sustained-release gel coated compositions |
WO2004041252A1 (en) | 2002-11-08 | 2004-05-21 | Egalet A/S | Controlled release carvedilol compositions |
DE602004025159D1 (en) | 2003-03-26 | 2010-03-04 | Egalet As | Matrix preparations for the controlled administration of drugs |
ATE495732T1 (en) | 2003-03-26 | 2011-02-15 | Egalet As | CONTROLLED RELEASE MORPHINE SYSTEM |
MXPA05011071A (en) * | 2003-04-21 | 2005-12-12 | Euro Celtique Sa | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same. |
BRPI0409652A (en) | 2003-04-24 | 2006-04-25 | Jagotec Ag | tablet, pharmaceutical packaging, disease treatment method, and tablet preparation method |
PT1658054E (en) | 2003-08-06 | 2007-09-18 | Gruenenthal Gmbh | Dosage form that is safeguarded from abuse |
US20050053655A1 (en) * | 2003-09-05 | 2005-03-10 | Pharmaceutical Industry Technology And Development Center | Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same |
MXPA06003454A (en) * | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Controlled release formulations of opioid and nonopioid analgesics. |
US8883204B2 (en) * | 2003-12-09 | 2014-11-11 | Purdue Pharma L.P. | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
EP1758557B1 (en) * | 2004-05-11 | 2011-07-13 | Egalet Ltd. | Swellable dosage form comprising gellan gum |
WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
US20060177380A1 (en) | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060193912A1 (en) * | 2005-02-28 | 2006-08-31 | Penwest Pharmaceuticals Co. | Controlled release O-desmethylvenlafaxine formulations |
GB0506982D0 (en) | 2005-04-06 | 2005-05-11 | Mw Encap Ltd | Abuse resistant capsules |
AU2006254554B2 (en) | 2005-06-03 | 2011-11-24 | Egalet Ltd | A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
PE20070325A1 (en) * | 2005-06-29 | 2007-05-12 | Alza Corp | ORAL DOSAGE FORMS THAT INCLUDE CARBAMATE-DERIVED COMPOUNDS |
US20080166407A1 (en) * | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
US8652529B2 (en) * | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
US20070190142A1 (en) | 2006-01-21 | 2007-08-16 | Abbott Gmbh & Co. Kg | Dosage forms for the delivery of drugs of abuse and related methods |
US20070264346A1 (en) * | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
US8445018B2 (en) * | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US20100291205A1 (en) * | 2007-01-16 | 2010-11-18 | Egalet A/S | Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse |
AU2008258596B2 (en) * | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
JP5774853B2 (en) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Pharmaceutical dosage form |
NZ592276A (en) | 2008-09-18 | 2012-12-21 | Purdue Pharma Lp | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID |
EP2700400A1 (en) * | 2009-01-26 | 2014-02-26 | Egalet Ltd. | Controlled release formulation with continuous efficacy |
AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
NZ594208A (en) | 2009-02-06 | 2012-10-26 | Egalet Ltd | Pharmaceutical compositions resistant to abuse |
NZ603579A (en) * | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
-
2010
- 2010-02-05 NZ NZ594208A patent/NZ594208A/en not_active IP Right Cessation
- 2010-02-05 ES ES10709791.7T patent/ES2607209T3/en active Active
- 2010-02-05 WO PCT/DK2010/000019 patent/WO2010088911A1/en active Application Filing
- 2010-02-05 US US12/701,429 patent/US8603526B2/en not_active Expired - Fee Related
- 2010-02-05 EP EP16196713.8A patent/EP3184105A1/en not_active Withdrawn
- 2010-02-05 EP EP10709791.7A patent/EP2393487B1/en not_active Not-in-force
- 2010-02-05 AU AU2010211376A patent/AU2010211376B2/en not_active Ceased
- 2010-02-05 DK DK10709791.7T patent/DK2393487T3/en active
- 2010-02-05 CA CA2751627A patent/CA2751627A1/en not_active Abandoned
-
2011
- 2011-07-28 IL IL214354A patent/IL214354A0/en unknown
- 2011-07-29 ZA ZA2011/05626A patent/ZA201105626B/en unknown
-
2013
- 2013-10-24 US US14/062,719 patent/US9168228B2/en not_active Expired - Fee Related
- 2013-11-19 AU AU2013257533A patent/AU2013257533B2/en not_active Ceased
-
2015
- 2015-09-21 US US14/859,800 patent/US9498446B2/en not_active Expired - Fee Related
-
2016
- 2016-10-14 US US15/293,867 patent/US10105321B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013257533A1 (en) | Pharmaceutical compositions resistant to abuse | |
ZA201105626B (en) | Pharmaceutical compositions resistant to abuse | |
HK1231408A1 (en) | Pharmaceutical composition | |
HK1218881A1 (en) | Pharmaceutical compositions | |
EP2451274A4 (en) | Pharmaceutical compositions | |
EP2240022A4 (en) | Pharmaceutical compositions | |
EP2373681A4 (en) | Pharmaceutical compositions | |
EP2379077A4 (en) | Pharmaceutical composition | |
GB0815852D0 (en) | Improvements relating to pharmaceutical compositions | |
IL219018A0 (en) | Pharmaceutical compositions | |
GB0919650D0 (en) | Pharmaceutical composition | |
GB0800659D0 (en) | Pharmaceutical Compositions | |
AU2009905147A0 (en) | Pharmaceutical Compositions | |
GB0901241D0 (en) | Pharmaceutical compositions | |
HU0900010D0 (en) | Improved pharmaceutical composition | |
GB0908970D0 (en) | Local pharmaceutical compositions | |
AU2010904996A0 (en) | Pharmaceutical compositions | |
GB0805807D0 (en) | Novel pharmaceutical compositions | |
GB0804485D0 (en) | Novel pharmaceutical compositions | |
GB0806156D0 (en) | Pharmaceutical compositions | |
GB0802024D0 (en) | Pharmaceutical compositions | |
GB0806283D0 (en) | Pharmaceutical compositions | |
EP2308842A4 (en) | Pharmaceutical compositions |